Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 4/2014

01-12-2014 | Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Optimizing ART Adherence: Update for HIV Treatment and Prevention

Authors: Reuben N. Robbins, Anya Y. Spector, Claude A. Mellins, Robert H. Remien

Published in: Current HIV/AIDS Reports | Issue 4/2014

Login to get access

Abstract

Optimal adherence to antiretroviral therapy (ART) is central to achieving viral suppression and positive health outcomes in HIV-infected individuals. Virally suppressed individuals can also reduce the risk of HIV transmission to uninfected partners. Hence, adherence to ART has become both an HIV treatment and an HIV prevention strategy. However, achieving optimal ART adherence can be challenging, especially over the long term. It is increasingly important for clinicians and researchers to be abreast of the most recent developments in the field as new biomedical approaches to treatment emerge and as guidelines for the use of pre-exposure prophylaxis (PrEP) are disseminated to providers serving HIV affected populations. Several reviews have described numerous ART adherence interventions that have been developed and/or tested with the most recent review including literature up to 2012. To augment the literature, we present a review of ART adherence interventions from 2013 to the present. We included peer-reviewed journals as well as abstracts from two key conferences.
Literature
1.
Meichenbaum D, Turk DC. Facilitating treatment adherence: a practitioner’s guidebook. The University of Michigan: Plenum Press; 1987. 310 p.CrossRef
2.
Hertogs K, Bloor S, Vroey VD, Eynde CD, Dehertogh P, Cauwenberge A, et al. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrobial Agents Chemotherapy. 2000;44(3):568–73.PubMedCentralPubMedCrossRef
3.
Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O’Shaughnessy MV, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;17(7):1051–8.CrossRef
4.
Kozal MJ, Rivet AK, Chiarella J, Schreibman T, Cornman D, Fisher W, et al. Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS. 2004;18(16):2185–9.PubMedCrossRef
5.
Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34(8):1115–21.PubMedCrossRef
6.
McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33(5):700–5.PubMedCrossRef
7.
Wood E, Hogg RS, Yip B, Harrigan PR, O’Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV infected adults who start highly active antiretroviral therapy when the CD4? cell count is 0.200 to 0.350 9 10(9) cells/L. Ann Intern Med. 2003;139:810–6.PubMedCrossRef
8.
Pasternak AO, de Bruin M, Jurriaans S, Bakker M, Berkhout B, Prins JM, et al. (2012) Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis 210(3)
9.
10.
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57.PubMedCrossRef
11.
Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 2010;51(4):392–400.PubMedCentralPubMedCrossRef
12.
Centers for Disease Control. Vital signs: HIV prevention through care and treatment. MMWR CDC Surveillance Summary. 2011;60(47):1618–23.
13.
Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.PubMedCentralPubMedCrossRef
14.
15.
Kashuba AD, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999;43:1817–26.PubMedCentralPubMed
16.
Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRef
17.
Grant RM. Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis. 2010;50(Supplement 3):S96–S101.PubMedCentralPubMedCrossRef
18.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.PubMedCentralPubMedCrossRef
19.
Nicol MR, Adams JL, Kashuba ADM (2013) HIV PrEP trials: the road to success. Clin Investig 3(3)
20.
Boffito M, Jackson A, Asboe D. Pharmacology lessons from chemoprophylaxis studies. Clin Infect Dis. 2014;59(supplement 1):S52–S4.PubMedCrossRef
21.
Wolf MS, Davis TC, Osborn CY, Skripkauskasa S, Bennett CL, Makoul G. Literacy, self-efficacy, and HIV medication adherence. Patient Educ Couns. 2007;65(2):253–60.PubMedCrossRef
22.
Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci. 2011;88(21–22):948–52.PubMedCentralPubMedCrossRef
23.
Pence BW. The impact of mental health and traumatic life experiences on antiretroviral treatment outcomes for people living with HIV/AIDS. J Antimicrob Chemother. 2009;63(4):636–40.PubMedCentralPubMedCrossRef
24.
Weiser SD, Frongillo EA, Ragland K, Hogg RS, Riley ED, Bangsberg DR. Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med. 2009;24(1):14–20.PubMedCentralPubMedCrossRef
25.
Rintamaki LS, Davis TC, Skripkauskas S, Bennett CL, Wolf MS. Social stigma concerns and HIV medication adherence. AIDS Patient Care STDs. 2006;20(5):359–68.PubMedCrossRef
26.
Tuller DM, Bangsberg D, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav. 2010;14(4):778–84.PubMedCentralPubMedCrossRef
27.
Golin CE, Liu H, Hays RD, Miller LG, Beck CK, Ickovics J, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17(10):756–65.PubMedCentralPubMedCrossRef
28.
Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. JAIDS J Acquir Immune Defic Syndr. 2006;43(Supplement 1):S23–35.CrossRef
29.
Amico KR, Harman J, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. JAIDS J Acquir Immune Defic Syndr. 2006;41(3):285–97.CrossRef
30.
Chaiyachati KH, Ogbuoji O, Price M, Suthar AB, Negussie EK, Bärnighausen T (2014) Interventions to improve adherence to antiretroviral therapy: a rapid systematic review. AIDS Suppl 2:S187-204
31.
Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an international association of physicians in AIDS care panel. Ann Intern Med. 2012;256:817–33.CrossRef
32.
Belzer ME, Naar-King S, Olson J, Sarr M, Thornton S, Kahana SY, et al (2013) The use of cell phone support for non-adherent HIV-infected youth and young adults: an initial randomized and controlled intervention trial. AIDS Behav
33.
Castro JG, Waldrop-Valverde D, Valverde EE (2013) An educational intervention with Hispanic HIV infected patients: a randomized study. Epidemiol 4(1).
34.
Robbins GK, Testa MA, Su M, Safren SA, Morse G, Lammert S, et al. Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384. HIV Clinical Trials. 2013;14(5):235–53.PubMedCentralPubMedCrossRef
35.
Kalichman S, Cherry C, Kalichman MO, Amaral C, White D, Cruess D, et al. Randomized clinical trial of HIV treatment adherence counseling interventions for people living with HIV and limited health literacy. JAIDS J Acquir Immune Defic Syndr. 2013;63(1):42–50.CrossRef
36.
Lewis MA, Uhrig JD, Bann CM, Harris JL, Furberg RD, Coomes C, et al. Tailored text messaging intervention for HIV adherence: a proof-of-concept study. Health Psychol. 2013;32(3):248–53.PubMedCrossRef
37.
Claborn KR, Leffingwell TR, Miller MB, Ellen Meier E, Stephens JR. Pilot study examining the efficacy of an electronic intervention to promote HIV medication adherence. AIDS Care. 2014;26(3):404–9.PubMedCrossRef
38.
Letourneau EJ, Ellis DA, Naar-King S, Chapman JE, Cunningham PB, Fowler S. Multisystemic therapy for poorly adherent youth with HIV: results from a pilot randomized controlled trial. AIDS Care. 2013;25(4):507–14.PubMedCrossRef
39.
Reznick OG, McCartney K, Gregorich SE, Zack B, Feaster DJ. An ecosystem-based intervention to reduce HIV transmission risk and increase medication adherence among inmates being released to the community. J Correct Health Care. 2013;19(3):178–93.PubMedCentralPubMedCrossRef
40.
Robbins RN, Mellins CA, Leu C, Rowe J, Warne P, Abrams E, et al. (2014) Enhancing lay counselor capacity to improve patient outcomes with multimedia technology. AIDS Behav. Forthcoming 2015.
41.
Bhana A, Mellins CA, Petersen I, Alicea S, Myeza N, Holst H, et al. The VUKA family program: piloting a family-based psychosocial intervention to promote health and mental health among HIV infected early adolescents in South Africa. AIDS Care. 2014;26(1):1–11.PubMedCrossRef
42.
Jones D, Bofil L, Aristegui I, Mattioli I, Ceccini D, Sued O, et al. (eds) (2014) COPA: Enhancing adherence, engagement, and retention in HIV Care in Argentina. 9th International Conference on HIV treatment and Prevention Adherence. Miami, Fl.
43.
Enriquez M, Hart K (eds) (2014) "Someone to Listen": Becoming adherent to HIV medication after repeated failure. 9th International Conference on HIV Treatment and Prevention Adherence. Miami, Fl.
44.
van der Straten A, Mayo A, Brown E, Amico KR, Cheng H, Laborde N, et al. (eds) (2014) Assessment of VOICE adherence support program (VASP) in the MTN-003 Trial. 9th International Conference on HIV treatment and Prevention Adherence. Miami, Fl.
45.
Rana A, van den Berg J, Lamy E, Beckwith CG (eds) (2014) Piloting an mHealth intervention to improve treatment adherence among newly diagnosed and non-adherent HIV positive patients. 9th International Conference on HIV treatment and Prevention Adherence. Miami, Fl.
46.
Ingersoll K, Dillingham R, Reynolds G, Freeman J, Hosseinbor A, Hettema J (eds) (2014) Feasibility and impact of a personalized bidirectional text messaging ART adherence tool for nonurban substance users. 9th International Conference on HIV treatment and Prevention Adherence. Miami, Fl.
47.
Dennis D, Abrams L, Morey T, Melker R (eds) (2014) Usability evaluation of SMART adherence system in HIV-positive patients. 9th International Conference on HIV treatment and Prevention Adherence. Miami, Fl.
48.
Schneider MP, Rotzinger A, Maestralli D, Bugnon O, Cavassini M, Parienti JJ. Adherence-enhancing program and retention to care in the Swiss Cohort. 9th International Conference on HIV Treatment and Prevention Adherence. Miami, Fl; 2014.
49.
Sevelius J, Johnson M, Saberi P (eds) (2014) Health Divas: a culturally relevant intervention to improve engagement in care among transgender women living with HIV. 9th International Conference on HIV treatment and Prevention Adherence. Miami, Fl.
50.
Teti M, Gerkovich M, Farnan R. Snapshots of adherence: photo-stories as a tool to promote medication use among people with HIV. 9th International Conference on HIV Treatment and Prevention Adherence. Miami, Fl; 2014.
51.
Lehrman S, Evans E, Brady K, Terrell C (eds) (2014) Early results from the Philadelphia Integrative Behavioral Health Initiative: Improved Retention in Care. 9th International Conference on HIV treatment and Prevention Adherence. Miami, Fl.
52.
Green K, Jones R, Ortiz-Ricard A (eds) (2014) Updating the evidence-based intervention pager messaging into a mobile application to improve adherence to antiretroviral treatment. 9th International Conference on HIV treatment and Prevention Adherence. Miami, Fl.
53.
Gross R, Zheng L, La Rosa A, Sun X, Rosenkranz S, Cardoso-Wagner S, et al. (eds) (2014) Partner-based intervention for adherence to second-line ART: a multinational trial (ACTG A5234). 2014 Conference on Retroviruses and Opportunistic Infections. Boston, Mass.
54.
Simoni JM, Wiebe JS, Sauceda JA, Huh D, Sanchez G, Longoria V, et al. A preliminary RCT of CBT-AD for adherence and depression among HIV-positive Latinos on the US-Mexico border: the Nuevo Dia study. AIDS Behav. 2013;17(8):2816–29.PubMedCentralPubMedCrossRef
55.
56.
57.
Ellis DA, Naar-King S, Cunningham PB, Secord E. Use of multisystemic therapy to improve antiretroviral adherence and health outcomes in HIV-infected pediatric patients: evaluation of a pilot program. AIDS Patient Care STDs. 2006;20(2):112–21.PubMedCrossRef
58.
McKay MM, Chase K, Baptiste D, Bell C, Coleman D, Madision S, et al. Family-level impact of the CHAMP family program: a community collaborative effort to support urban families and reduce youth HIV risk exposure. Fam Process. 2004;77:77–91.
59.
Petersen I, Bhana A, Baillie K (2011) The feasibility of adapted group-based interpersonal therapy (IPT) for the treatment of depression by community health workers within the context of task shifting in South Africa. Commun Mental Health J:1–6.
60.
Bosworth K, Espelage D, DuBay T, Daytner G, Karageorge K. Preliminary evaluation of a multimedia violence prevention program for adolescents. Am J Health Behav. 2000;24:268–80.CrossRef
61.
Bartholomew LK, Shegog R, Parcel GS, et al. Watch, discover, think, and act: a model for patient education program development. Patient Educ Couns. 2000;39(2):253–68.PubMedCrossRef
62.
Rubin DH, Leventhal JM, Sadock RT, et al. Educational intervention by computer in childhood asthma: a randomized clinical trial testing the use of a new teaching intervention in childhood asthma. Pediatrics. 1986;77:1–10.PubMed
63.
Brown SJ, Lieberman DA, Gemeny BA, Fan YC, Wilson DM, Pasta DJ. Educational video game for juvenile diabetes: results of a controlled trial. Med Inform (Lond). 1997;22:77–89.CrossRef
64.
French D. Influence smoking cessation with computer-assisted instruction. AAOHN. 1986;34:391–4.
65.
Tingen MS, Grimling LF, Bennet G, Gibson EM, Renew MM. A pilot study of preadolescents to evaluate a video game-based smoking prevention strategy. J Addict Nurs. 1997;9:118–24.CrossRef
66.
Reis J, Riley W, Baer J. Interactive multimedia preventive alcohol education: an evaluation of effectiveness with college students. J Educ Comput Res. 2000;23:41–65.CrossRef
67.
Safren S, Otto MW, Worth JL, Salomon E, Johnson W, Mayer K, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Re Ther. 2001;39(10):1151–62.CrossRef
68.
Remien RH, Mellins CA, Robbins RN, Kelsey R, Rowe J, Warne P, et al. Masivukeni: development of a multimedia based antiretroviral therapy adherence intervention for counselors and patients in South Africa. AIDS Behav. 2013;17(6):1979–91.PubMedCentralPubMedCrossRef
69.
Remien RH, Stirratt MJ, Dognin J, Day E, El-Bassel N, Warne P. Moving from theory to research to practice. Implementing an effective dyadic intervention to improve antiretroviral adherence for clinic patients. J Acquir Immune Defic Syndr. 2006;43 Suppl 1:S68–78.
70.
Remien RH, Mellins C (2007) Long-term psychosocial challenges for people living with HIV: let’s not forget the individual in our global response to the pandemic. AIDS Supplement 5:S55-63.
71.
Remien R, Hirky E, Johnson MO, Weinhardt LS, Whittier D, Le GM. Adherence to medication treatment: facilitators and barriers among a diverse sample of HIV+ men and women in four U.S. Cities. AIDS Behav. 2003;7(1):61–72.PubMedCrossRef
72.
de Bruin M, Viechtbauer W, Schaalma HP, Kok G, Abraham C, Hospers HJ. Standard care impact on effects of highly active antiretroviral therapy adherence interventions: A meta-analysis of randomized controlled trials. Arch Intern Med. 2010;170(3):240–50.PubMedCrossRef
73.
Wagner GJ, Kanouse DE. Assessing usual care in clinical trials of adherence interventions for highly active antiretroviral therapy. JAIDS J Acquir Immune Defic Syndr. 2003;33(2):276–77.CrossRef
74.
Safren S, O’Cleirigh C, Bullis J. CBT for adherence and depression (CBT-AD) in HIV-infected injection drug users: an RCT. J Consult Clin Psychol. 2011;80(3):404–15.CrossRef
75.
Safren SA, O’Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012;80(3):404.PubMedCentralPubMedCrossRef
76.
Safren S, O’Cleirigh CM, Tan J, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009;28(1):1–10.PubMedCentralPubMedCrossRef
Metadata
Title
Optimizing ART Adherence: Update for HIV Treatment and Prevention
Authors
Reuben N. Robbins
Anya Y. Spector
Claude A. Mellins
Robert H. Remien
Publication date
01-12-2014
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 4/2014
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-014-0229-5

Other articles of this Issue 4/2014

Current HIV/AIDS Reports 4/2014 Go to the issue

Treatment as Prevention (RM Granich, Section Editor)

Treatment as Prevention—Where Next?

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Contraceptive Methods and Risk of HIV Acquisition or Female-to-Male Transmission

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Combination HIV Prevention Interventions: The Potential of Integrated Behavioral and Biomedical Approaches

Treatment as Prevention (RM Granich, Section Editor)

Reaching the Unreached: Treatment as Prevention as a Workable Strategy to Mitigate HIV and Its Consequences in High-Risk Groups

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Review of Recent Behavioral Interventions Targeting Older Adults Living with HIV/AIDS

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Palliative HIV Care: Opportunities for Biomedical and Behavioral Change
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits